Menu
MorphoSys US

MorphoSys'
clinical pipeline

You are here

  1. Home
  2. Pipeline
  3. Pipeline

Based on our advanced antibody research, we are developing novel therapies for people with cancer and autoimmune diseases. Here you can find an overview of the clinical studies on our own drug candidates and the most advanced clinical programs of our partners.

Our clinical pipeline

  • Phase 1
  • Phase 2
  • Phase 3
  • Market
Program
Partner
Indication
Phase

Tafasitamab-cxix (MOR208)

Partner

Incyte Corporation*

Indication

Phase

Relapsed or refractory diffuse large B cell lymphoma (DLBCL) (L-MIND) (Monjuvi® - U.S. only – accelerated approval)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Relapsed or refractory diffuse large B cell lymphoma (DLBCL) (B-MIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory follicular or marginal zone lymphoma (FL; MZL) (inMIND)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (COSMOS)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Diffuse large B cell lymphoma (DLBCL) (First-MIND)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

*Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

  • MOR208 (former XmAb®5574)
  • INN: tafasitamab
  • Target: CD19
More Information on Tafasitamab (MOR208)

Felzartamab (MOR202)

Partner

 

Indication

Phase

Anti-PLA2R-positive membranous nephropathy (M-PLACE)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Anti-PLA2R-positive membranous nephropathy (New-PLACE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

* Felzartamab (MOR202/TJ202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.

  • A fully human HuCAL antibody
  • Target: CD38
More Information on Felzartamab (MOR202)

* Tafasitamab: Global Collaboration and License Agreement with Incyte Corporation; co-commercialization in the U.S.; Incyte has exclusive commercialization rights outside the U.S.

Clinical programs developed by our partners (selection)

  • Phase 1
  • Phase 2
  • Phase 3
  • Market
Program
Partner
Indication
Phase

Tremfya® (guselkumab)

Partner

Janssen/J&J

Indication

Phase

Plaque psoriasis
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Psoriatic arthitis (PsA)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Palmoplantar pustolosis (Japan only)
Phase 1 Phase 2 Phase 3 Market (Current Phase)
Palmoplantar-non-pustular psoriasis (G-PLUS)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Chronic plaque psoriasis (pediatric participants) (PROTOSTAR)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Crohn's disease (GALAXI)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Ulcerative colitis (QUASAR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Familial adenomatous polyposis
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

Felzartamab (MOR202)

Partner

I-Mab Biopharma*

Indication

Phase

Multiple myeloma (MM) (combo with lenalidomide)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Multiple myeloma (MM)*
Phase 1 Phase 2 (Current Phase) Phase 3 Market

Otilimab (MOR103/GSK3196165)

Partner

GlaxoSmithKline

Indication

Phase

Rheumatoid arthritis (contRAst 1-3)*
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Severe pulmonary COVID-19 related disease (OSCAR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market

*Fully outlicensed to GlaxoSmithKline.

  • A fully human HuCAL antibody
  • Target: GM-CSF

Gantenerumab

Partner

Roche

Indication

Phase

Early Alzheimer's disease (GRADUATE 1+2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Mild Alzheimer's disease (Marguerite RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Prodromal Alzheimer's disease (Scarlett RoAD) (OLE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Rollover study on long-term administration of gantenerumab
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Alzheimer's disease (Brain Shuttle Gantenerumab, RG6102)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody
  • Target: Amyloid-beta

Additional Information:

Anetumab ravtansine

Partner

Bayer AG

Indication

Phase

Mesothelioma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Cancer, multi-indications
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

Ianalumab (VAY736)

Partner

Novartis

Indication

Phase

ADCC mediated B cell depletion & BAFF-R blockade (AMBER)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Idiopathic pulmonary fibrosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Systemic Lupus Erythematosus (SLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: BAFF-R

Additional information:

Setrusumab (BPS804)

Partner

Novartis/Mereo/Ultragenyx

Indication

Phase

Brittle bone disease (Type I, III, IV) (ASTEROID)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: Sclerostin

Additional information:

Bimagrumab

Partner

Novartis

Indication

Phase

Type 2 diabetes
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody 
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

Utomilumab (PF-05082566)

Partner

Pfizer

Indication

Phase

Breast cancer (AVIATOR)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Breast cancer (combo with avelumab) (InCITe)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors (combo with ISA101b vaccination)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced Malignancies (combo with avelumab, PF-04518600 & CMP-001 (TLR9 agonist)) (JAVELIN Medley)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Advanced malignancies (combo with avelumab & PF-04518600)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Refractory large B cell lymphoma (combo with Axicabtagene ciloleucel) (ZUMA-11)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: 4-1BB (CD137)
  • Alias: PF-05082566

Additional Information:

Xentuzumab (BI-836845)

Partner

Boehringer Ingelheim

Indication

Phase

Breast cancer
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Castration-resistant prostate cancer (CRPC) (combo with enzalutamide)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody
  • Target: IGF-1

Additional Information:

MOR210

Partner

I-Mab Biopharma*

Indication

Phase

Relapsed or refractory advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market

* I-Mab receives exclusive rights in China, Hong Kong, Macao, Taiwan and South Korea, while MorphoSys retains rights in other parts of the world.

* Felzartamab (MOR202): Sublicensed to I-Mab for development in China, Hong Kong, Macao and Taiwan.
* MOR210: Sublicensed to I-Mab for development in China, Hong Kong, Macao, Taiwan and South Korea.

Physicians and Patients

Physicians interested in learning more about MorphoSys-sponsored clinical trials should contact: medical@morphosys.com.

Patients are kindly asked to contact their treating physicians if they are interested in participating in any of MorphoSys's clinical trials.

Disclaimer
MorphoSys’s product candidates are investigational and are currently not approved for the treatment of any disease or condition anywhere in the world. They cannot be prescribed or purchased for therapy at present.
The MorphoSys website may contain information on drug candidates and clinical trials sponsored by MorphoSys with the intention of increasing the transparency of the company’s clinical research. There is no guarantee any product will be approved in the sought after indication.
Information contained within this website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information available through the site. MorphoSys may amend the information at any time without notice.

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the MorphoSys US website which is intended for US residents.

Do you wish to proceed?

Yes No

You are leaving morphosys.com and will be transferred to the Monjuvi(®) US website which is intended for US residents.

Do you wish to proceed?

Yes No